These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Parkinsonism-inducing neurotoxin MPP+: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA. Kitayama S; Shimada S; Uhl GR Ann Neurol; 1992 Jul; 32(1):109-11. PubMed ID: 1642464 [TBL] [Abstract][Full Text] [Related]
5. Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity. Van Kampen JM; McGeer EG; Stoessl AJ Synapse; 2000 Sep; 37(3):171-8. PubMed ID: 10881039 [TBL] [Abstract][Full Text] [Related]
6. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Wall SC; Gu H; Rudnick G Mol Pharmacol; 1995 Mar; 47(3):544-50. PubMed ID: 7700252 [TBL] [Abstract][Full Text] [Related]
8. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium. Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999 [TBL] [Abstract][Full Text] [Related]
9. Induction by low Na+ or Cl- of cocaine sensitive carrier-mediated efflux of amines from cells transfected with the cloned human catecholamine transporters. Pifl C; Agneter E; Drobny H; Reither H; Singer EA Br J Pharmacol; 1997 May; 121(2):205-12. PubMed ID: 9154329 [TBL] [Abstract][Full Text] [Related]
10. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Pristupa ZB; McConkey F; Liu F; Man HY; Lee FJ; Wang YT; Niznik HB Synapse; 1998 Sep; 30(1):79-87. PubMed ID: 9704884 [TBL] [Abstract][Full Text] [Related]
11. Inhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporter. Clarke PB; Reuben M Br J Pharmacol; 1995 Jan; 114(2):315-22. PubMed ID: 7881731 [TBL] [Abstract][Full Text] [Related]
12. Involvement of the NH2 terminal domain of catecholamine transporters in the Na(2+) and Cl(-)-dependence of a [3H]-dopamine uptake. Syringas M; Janin F; Giros B; Costentin J; Bonnet JJ Br J Pharmacol; 2001 Jun; 133(3):387-94. PubMed ID: 11375255 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. Staal RG; Sonsalla PK J Pharmacol Exp Ther; 2000 May; 293(2):336-42. PubMed ID: 10773000 [TBL] [Abstract][Full Text] [Related]
14. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Buck KJ; Amara SG Mol Pharmacol; 1995 Dec; 48(6):1030-7. PubMed ID: 8848002 [TBL] [Abstract][Full Text] [Related]
15. A model of chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) within catecholaminergic neurons. Johannessen JN Neurotoxicology; 1991; 12(2):285-302. PubMed ID: 1956587 [TBL] [Abstract][Full Text] [Related]
16. Novel N-substituted 3 alpha-[bis(4'-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter. Agoston GE; Wu JH; Izenwasser S; George C; Katz J; Kline RH; Newman AH J Med Chem; 1997 Dec; 40(26):4329-39. PubMed ID: 9435902 [TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells. Gélinas S; Martinoli MG J Neurosci Res; 2002 Oct; 70(1):90-6. PubMed ID: 12237867 [TBL] [Abstract][Full Text] [Related]
18. N-(3-lodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(3',4'-dichloro phenyl)nortropane (beta-CDIT), a tropane derivative: pharmacological characterization as a specific ligand for the dopamine transporter in the rodent brain. Garreau L; Emond P; Belzung C; Guilloteau D; Frangin Y; Besnard JC; Chalon S J Pharmacol Exp Ther; 1997 Jul; 282(1):467-74. PubMed ID: 9223589 [TBL] [Abstract][Full Text] [Related]
19. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Kilbourn MR; Kuszpit K; Sherman P Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034 [TBL] [Abstract][Full Text] [Related]
20. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys. Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]